FitPeo , a healthcare technology company founded by Prabhat, is making waves in the industry with its groundbreaking approach to patient care. Combining cutting-edge technology with a human touch, FitPeo is redefining the patient-provider relationship and empowering individuals to take charge of their health.

The inspiration behind FitPeo stems from Prabhat’s personal experience with the healthcare system. After a traumatic accident, Prabhat encountered delays and miscommunication in receiving urgent medical attention. This eye-opening event revealed a significant gap in the healthcare system and led to the birth of an innovative solution – FitPeo.

FitPeo’s platform connects patients and providers through Remote Patient Monitoring, Chronic Care Management, and Telehealth services. With a focus on personalized care, the company has already served over 1000 patients, with plans to onboard an additional 400 patients by September 2023. Projections indicate exponential growth, with 5000 more patients expected to join in the coming months.

“Our goal is to provide better healthcare, increase patient retention, and optimize fragmented information,” says Prabhat. “We want to help doctors reduce the time it takes to initiate these programs and provide their patients with the best care. Monitoring patients in real-time will also reduce their need for frequent physical visits, ultimately minimizing medical emergencies.”

FitPeo’s platform goes beyond traditional healthcare services. In addition to Remote Patient Monitoring and Telehealth, the company provides Behavioral Health Integration and Transitional Care Management. This comprehensive approach sets FitPeo apart, as no other company currently offers such a wide array of services in one place.

“Our team is composed of dedicated and passionate individuals who truly believe in our mission,” notes Prabhat. “Though starting a company has its challenges, we have found remarkable people who share our vision of making healthcare more accessible, caring, and rewarding.”

FitPeo’s commitment to patient care and data-driven solutions has garnered praise and attention from users. Patients appreciate the human touch and personalized care provided by the platform, making them feel well-supported and cared for between doctor’s visits. For individuals managing chronic conditions like diabetes, FitPeo’s trending graph empowers them to track their health over time and prevent medical emergencies.

With its success in revolutionizing healthcare, FitPeo is now seeking its first round of funding in 2023 to fuel further growth and expand its reach. As the company continues to evolve and make an impact, it is positioned to shape the future of patient-centric healthcare, benefiting communities worldwide.

FUJIFILM India has done the installation of the new MRI machine Echelon Smart 1.5 Tesla in Sarvodaya Hospital, Greater Noida West (Noida Extension). The new MRI machine by FUJIFILM India provides functions for patient-friendly acoustic noise reduction (Smart Comfort), operator-friendly operation support and environment-friendly low power consumption.

The device is a 1.5T Superconductive MRI system with the high Image quality of the high magnetic field achieved by FUJIFILM technology and with a flexible site layout inherited from a permanent magnet MRI system.

Divyanu Gupta, Director, Sarvodaya Hospital, Greater Noida West said, “As a hospital, we have always looked forward to expanding our care facilities and bringing the best of technologies and newer dimensions to enhance the community’s healthcare infrastructure. It is very crucial for us to integrate evolving technologies into our system so that patients receive healthcare services of global standards.”

The MRI system has a power consumption of 29 kVA under general conditions and comes with smart technologies including SmartECO, SmartSPACE, SmartCOMFORT, SmartSPEED, and SmartQUALITY. While SmartECO reduces heat generation and provides economical running costs, SmartSPACE has a small footprint and flexible layout.

SmartCOMFORT features soft sound technology that provides a 94 per cent reduction in noise and offers quiet scanning without any compromise with Image Resolution and applies to SE, FSE, FIR, GRE, and DWI sequences. SmartSPEED features Autopose for Brain and Spine under a quick scan plan, besides Whole Body Diffusion, IsoFSE –Single volume acquisition to generate isotropic images in all planes and RADAR- Versatile motion artefact Reduction.

Koji Wada, Managing Director, FUJIFILM India, said, “It is for the first time that the MRI machine comprising myriads of smart technologies developed by Fujifilm is being installed in a hospital in Greater Noida. We are delighted to be able to contribute to upgrading the healthcare quality for the citizens of Greater Noida as well as nearby areas.”

>>>

Emids, a transformation and digital engineering solution for the healthcare and life sciences industry has launched its Generative AI platform, ‘EPulseAI’ by Emids for the healthcare industry.

The platform is targeted at all participants in the healthcare ecosystem in the US—payers, providers, and tech companies, enabling them to drive better outcomes for patients. EPulseAI accelerates product engineering and enhances productivity across the entire product development lifecycle by as much as 50 per cent

The implications of Generative AI in healthcare are truly remarkable. AI is redefining the way we process healthcare data to diagnose diseases, develop treatments and even prevent them altogether. We are thrilled to launch EPulseAI by Emids at a time when the healthcare industry is poised for this digital transformation journey with AI at its core. It is a purpose-built solution that empowers healthcare enterprises to accelerate and expand their Generative AI capabilities,” said Sean Narayanan, Chief Executive Officer at Emids.

Developed in-house, this Generative AI platform kicks off AI centers of excellence in Bangalore and Tennessee for Emids. The platform assists clients in streamlining activities from product ideation to rollout. The integration of EPulseAI into the product development process will enable better products that can improve the quality of medical care, enhance patient outcomes, and elevate customer experience, said the company.

Previously time-consuming tasks that would require several hours of manual effort can now be accomplished in just a few minutes through the new user interface based on Generative AI, resulting in an impressive user experience with human-like interaction. This streamlined approach not only saves time and resources but also paves the way for remarkable advancements in healthcare operations, ultimately benefitting all stakeholders involved.

In a major boost to medical infrastructure, the United Kingdom’s National Health Service (NHS) delegation visited India on Friday (August 4) to launch the India-UK healthcare alliance to promote excellence in the healthcare sector. The initiative is aimed towards providing a platform for healthcare institutions in the two countries and creating synergistic partnerships in order to improve the outcome of services.

According to news agency ANI, a high-powered delegation from the UK’s Health, Education, research and clinical practice sectors, including Prof Stephen Powis, National Medical Director of NHS England, Prof Simon Gregory MBE, Medical Director for Primary Care, Workforce Training and Education Directorate NHS England, Prof Geeta Menon, Postgraduate Dean, Workforce Training and Education Directorate NHS England and Prof Parag Singhal, Chief Executive of BAPIO Training Academy, were part of the launch.

Chandru Iyer, British Deputy High Commissioner to Karnataka and Kerala, said, “This is a wonderful initiative which brings the two countries together and collaborates together in promoting excellence in the field of healthcare and healthcare skilled resources. This is a continuation of some great initiatives around the India – UK corridor.”

“India and the UK worked closely together for the development of vaccines during the COVID pandemic. Going forward, there will be a lot of opportunities not just in drugs but in many technologies that are being developed including digital healthcare and artificial intelligence,” added Professor Stephen Powis, National Medical Director of NHS, England.

The 2030 Roadmap for India-UK future relations was launched on May 4, 2021, at a virtual summit between Prime Minister Narendra Modi and then UK PM Boris Johnson. The roadmap set out the jointly held vision for a reinvigorated and stronger relationship between the UK and India over the next ten years.

Roche announced the expansion of their Global Business Partnership Agreement with Sysmex. As part of the renewed framework, the companies strengthen their commitment to their long-standing partnership. Roche has been collaborating with Sysmex for 25 years and through the renewed terms, Roche will continue to offer Sysmex’ hematology products, complementing their total lab solutions portfolio.

The updated non-exclusive agreement also introduces a new area of collaboration with an additional eco-social agreement to jointly explore more sustainable diagnostic solutions. By taking their long-standing collaboration beyond the current portfolio, both companies are committed to pursue more sustainable solutions.

“We are delighted to expand our 25-year partnership with Sysmex in the area of hematology and in exploring more sustainable diagnostics solutions. Roche and Sysmex both have a long-standing history of delivering reliable and innovative solutions for patients and I am very happy to see this collaboration grow,” said Matt Sause, CEO of Roche Diagnostics.

“We are pleased to announce the renewal of our partnership with Roche, reaffirming our commitment to long-term collaboration. Developing our partnerships in the field of diagnostics even further and addressing enduring eco-social challenges represents a significant milestone in advancing our alliance to the next level. Together, we firmly believe in making even greater contributions to our customers in laboratories and creating a sustainable society,” said Kaoru Asano, President of Sysmex Corporation.
>>>

Peijia Medical, a leading Chinese domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets, announced  that the first Chinese patient of the multi-center registration clinical trial for TaurusTrio™ Transcatheter Aortic Valve Replacement (TAVR) system has been enrolled. TaurusTrio™ is the licensed-in Trilogy™ Heart Valve System for Aortic Regurgitation (AR) from JenaValve Technology, Inc. The first implant was successfully completed by Professors Yongjian Wu and Guangyuan Song at Beijing An Zhen Hospital, Capital Medical University on July 26, 2023.

“We are pleased to have safely implanted the first patient in China with the TaurusTrio™ TAVR System,” said Dr. Yi Zhang, Chief Executive Officer of Peijia Medical. “The trial reinforces our goals of improving care in the field of cardiology and expanding TAVR systems within China. We are looking forward to our continued partnership with American company, JenaValve and presenting further data from the clinical trial at a future date.”

The clinical trial of the TaurusTrio™ TAVR system is designed to assess the safety and efficacy of the system for treating patients with native symptomatic, severe AR, who are judged by a Heart Team (including a cardiac surgeon), to be at high or greater risk for surgical aortic valve replacement. The result of this clinical trial would be included in the Company’s future submission of registration application to the National Medical Products Administration (NMPA).

As of now, no transfemoral TAVR system for AR has been approved by the NMPA in China. In June 2023, TaurusTrio™ TAVR system was accepted by the Special Review and Approval Procedure for innovative medical devices of the NMPA.

In January 2022, Peijia Medical obtained an exclusive license from JenaValve for developing, manufacturing and commercializing Trilogy™ Heart Valve System in the Greater China region. On May 12, 2023, the successful completion of the first two commercial implants with the Trilogy™ Heart Valve System took place in Hong Kong.

Lupin Digital Health (LDH), India’s leading Cardiac Digital Therapeutics company, announced the launch of its newest offering, LyfeTM Digital Heart Failure Clinic in India. This groundbreaking e-clinic aims to help cardiologists and caregivers manage heart failure patients effectively from the comfort of their homes.

Heart failure affects over 10 million Indians today and is a progressive condition leading to repeated hospitalizations and is the leading cause of cardiac deaths. The LyfeTM Digital Heart Failure (HF) Clinic has been developed to address the growing burden on healthcare infrastructure due to increasing heart failure instances in India. It combines in-clinic consultation with at-home patient monitoring and care. A team of experts, including paramedics, nurses, cardiotherapists, health coaches and care managers, work together with the treating cardiologist to deliver improved patient health outcomes. The system is equipped with advanced technology, providing doctors with real-time updates and patients with personalized care pathways, emergency services and educational resources.

Commenting on the launch, Rajeev Sibal, President – India Region Formulations, Lupin Limited, said, “The launch of LyfeTM Digital HF clinic is a significant milestone in transforming cardiac care in India. We would like to partner with every cardiologist in India, augmenting them with a multidisciplinary team of experts to help them better manage their heart failure patients. Our solution combines AI-guided software and FDA/CE-approved devices to provide clinically actionable alerts and insights.”

“We are thrilled to introduce the LyfeTM Digital HF Clinic solution in India, a pioneering solution that brings cardiac care right to the homes of patients. Our aim is to support cardiologists and caregivers in effectively managing heart failure, ensuring improved health outcomes for patients. The initial results of this new initiative have been encouraging, with 88% compliance, improved biovitals, and reduced re-hospitalization. We are committed to making this innovative solution accessible to as many patients as possible through collaborations with cardiologists and hospitals”, said Sidharth Srinivasan, CEO, Lupin Digital Health.

Lupin Digital Health has recently partnered with the American College of Cardiology (ACC), further solidifying its commitment to drive innovation in cardiac care. This collaboration allows LDH to leverage ACC’s patient education resources, guidance on care pathways, and clinical inputs, empowering healthcare professionals and caregivers to deliver optimal patient care.